On June 5, 2026, Jean Jacques Bienaime, serving as a director at Immunome Inc. (NASDAQ:IMNM), executed a complex series of open market transactions involving the company's common equity. According to recent Securities and Exchange Commission (SEC) filings, the director engaged in simultaneous buy and sell activities that resulted in a net neutral position change but triggered specific regulatory profit provisions.
Mr. Bienaime initiated the activity by selling 10,500 shares of Immunome common stock. These sales were executed at prices ranging between $19.41 and $19.44 per share, generating gross proceeds totaling $203,820. In a concurrent move, the director acquired an identical aggregate quantity of 10,500 shares. The acquisition costs for these repurchased shares ranged from $19.27 to $19.48 per share, culminating in a total purchase value of $204,260.
Footnotes attached to the SEC filing clarify that the sale and reacquisition of the same aggregate number of shares occurred on the same calendar day, June 5, 2026. This specific transaction structure resulted in the realization of a short-swing profit amounting to $155. This profit was derived from a subset of the activity involving 1,000 shares purchased at $19.27 per share and subsequently matched with sales. Under regulatory requirements, Mr. Bienaime has agreed to remit this $155 profit directly to Immunome Inc.
Following the execution of these transactions, Mr. Bienaime's direct ownership stake in Immunome Inc. stands at 43,415 shares. The current market price of the stock is recorded at $18.40, which represents a decline from the price levels observed during the director's transaction window. Despite this recent pullback, the equity has demonstrated substantial momentum over the trailing twelve months, delivering a total return of 98%. Valuation metrics from InvestingPro suggest the stock may be trading above its estimated Fair Value at present levels.
Beyond corporate governance activities, Immunome Inc. has reported significant clinical advancements regarding its desmoid tumor therapeutic candidate, varegacestat. The company presented comprehensive data from its Phase 3 RINGSIDE trial during the American Society of Clinical Oncology Annual Meeting. The trial cohort consisted of 156 patients and achieved its primary endpoint with statistical significance.
The clinical data indicated an 84% reduction in the risk of disease progression or death when compared to the placebo control group. The analysis yielded a hazard ratio of 0.16 and a p-value of less than 0.0001. Following the release of these results, Immunome formally submitted a New Drug Application to the U.S. Food and Drug Administration for varegacestat.
Market participants have reacted to the clinical data with upward revisions in price targets. Truist Securities raised its price target on Immunome to $37, maintaining a Buy rating based on the drug's anticipated market impact. Concurrently, Barclays initiated coverage on the stock with an overweight rating and established a price target of $36. The company projects a potential commercial launch of varegacestat within the next twelve months, contingent upon regulatory approval.
The biotechnology sector faces ongoing volatility as investors weigh clinical success against regulatory timelines. While the RINGSIDE trial results provide strong evidence for varegacestat's efficacy, the New Drug Application process introduces uncertainty regarding approval timing and commercial execution. The simultaneous nature of the director's transactions highlights the precision required in equity management, while the stock's current valuation relative to fair value estimates suggests potential sensitivity to future catalysts.